RESUMO
We studied 48 patients with Behçet disease to determine the clinical spectrum of the disease. We also compared the seropositivity of patients for hepatitis B (HBV) and C (HCV) infection with a healthy control group to determine whether there is an association. The major physical findings were oral aphthosis 93.8%, genital aphthosis 77.1% and ocular manifestations 64.6%. No patients were HCV antibody seropositive, but 3 of the control group (3.1%) tested seropositive. One patient (2.1%) and 2 in the control group (2.1%) tested positive for both HBV surface antigen and HBV core antibody. The differences were not statistically significant. There is, therefore, no case for recommending viral screening for HBV and HCV in Behçet disease patients at present.
Assuntos
Síndrome de Behçet/epidemiologia , Hepatite B/epidemiologia , Hepatite C/epidemiologia , Adulto , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Aspartato Aminotransferases/sangue , Síndrome de Behçet/complicações , Síndrome de Behçet/diagnóstico , Bilirrubina/sangue , Estudos de Casos e Controles , Comorbidade , Ensaio de Imunoadsorção Enzimática , Feminino , Hepatite B/complicações , Hepatite B/diagnóstico , Hepatite B/metabolismo , Antígenos do Núcleo do Vírus da Hepatite B/sangue , Antígenos de Superfície da Hepatite B/sangue , Hepatite C/complicações , Hepatite C/diagnóstico , Hepatite C/metabolismo , Anticorpos Anti-Hepatite C/sangue , Hospitais Universitários , Humanos , Immunoblotting , Irã (Geográfico)/epidemiologia , Masculino , Programas de Rastreamento , Vigilância da População , Estudos SoroepidemiológicosRESUMO
We studied 48 patients with Behcet disease to determine the clinical spectrum of the disease. We also compared the seropositivity of patients for hepatitis B [HBV] and C [HCV] infection with a healthy control group to.determine whether there is an association. The major physical findings were oral aphthosis 93.8%, genital aphthosis 77.1% and ocular manifestations 64.6%. No patients were HCV antibody seropositive, but 3 of the control group [3.1%] tested seropositive. One patient [2.1%] and 2 in the control group [2.1%] tested positive for both HBV surface antigen and HBV core antibody. The differences were not statistically significant. There is, therefore, no case for recommending viral screening for HBV and HCV in Behcet disease patients at present
